Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons
Numerous studies suggest that the dopamine transporter (DAT), responsible for dopamine reuptake, may act as a vulnerability factor in the pathogenesis of Parkinson's disease (PD) and the vesicular monoamine transporter (VMAT2), responsible for its vesicular storage, as a neuroprotective factor....
Saved in:
Published in | Journal of comparative neurology (1911) Vol. 479; no. 2; pp. 198 - 215 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
08.11.2004
|
Subjects | |
Online Access | Get full text |
ISSN | 0021-9967 1096-9861 |
DOI | 10.1002/cne.20323 |
Cover
Summary: | Numerous studies suggest that the dopamine transporter (DAT), responsible for dopamine reuptake, may act as a vulnerability factor in the pathogenesis of Parkinson's disease (PD) and the vesicular monoamine transporter (VMAT2), responsible for its vesicular storage, as a neuroprotective factor. However, the relevance of each on the differential vulnerability of midbrain DA cells remains uknown. Here we studied the relationship between the expression pattern (mRNA and protein) of both transporters and the differential vulnerability of midbrain DA cells in a model of PD (intracerebroventricular injection of 6‐OHDA in rats) and in monkey and human midbrain. Our results revealed that the expression patterns for VMAT2 mRNA and protein and DAT mRNA are similar, with the highest levels in the rostromedial region of substantia nigra (SNrm), followed by the caudoventral region of SN (SNcv), the ventral tegmental area and pigmented parabrabraquial nucleus (VTA/PBP), and finally the linear and interfascicular nuclei (Li/IF). In contrast, the expression of DAT protein in rats, monkeys, and humans followed a caudoventrolateral‐to‐rostrodorsomedial decreasing gradient (SNcv > SNrm > VTA/PBP > Li/IF), matching the degeneration profile observed after intracerebroventricular injection of 6‐OHDA and in PD. In addition, DAT blockade made all midbrain DA cells equally resistant to 6‐OHDA. These data indicate that DAT protein levels, but not DAT mRNA levels, are closely related to the differential vulnerability of midbrain DA cells and that this relationship is unaffected by the relative levels of VMAT2. Furthermore, the difference between DAT mRNA and protein profiles suggests internuclear differences in its posttransductional regulation. J. Comp. Neurol. 479:198–215, 2004. © 2004 Wiley‐Liss, Inc. |
---|---|
Bibliography: | Centros de Investigación de Enfermedades Neurológicas Fondo de Investigaciones Sanitarias - No. 01/1126 istex:4CBC1EE1CCA5122BB5B7D61EB852CBB6D60971CA ark:/67375/WNG-NRBM8Q2D-L ArticleID:CNE20323 Fundación Canaria de Investigación y Salud Consejeria de Educación del Gobierno Autónomo de Canarias - No. PI2001/054 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
ISSN: | 0021-9967 1096-9861 |
DOI: | 10.1002/cne.20323 |